Who Paid My Doc
A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study)
Research payments
$509,683
Through program year 2023, $509,683 in research payments was reported against A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study), across 30 payments, paid by Dompe Farmaceutici S.p.A..
- Paid by
- Dompe Farmaceutici S.p.A.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $509,683 | 30 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sezen Karakus Baltimore, MD Named on 6 payments
- John Goosey Houston, TX Named on 6 payments
- Giacomina Massaro-Giordano Philadelphia, PA Named on 4 payments
- Sherif El Harazi Glendale, CA Named on 4 payments
- Pedram Hamrah Wellesley, MA Named on 4 payments
- Joseph Christenbury Atlanta, GA Named on 3 payments
- Melissa Toyos Memphis, TN Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.